Petition to the Food and Drug Administration to ban troglitazone/Rezulin due to its causing several cases of liver failure. Washington, D.C.: Public Citizen, 1998. (HRG Publication #1449).
Letter to Minnie Baylor-Henry, Director, Division of Drug Marketing, Advertising and Communications, Food and Drug Administration. Washington, D.C.: Public Citizen, 6 January 1999.
Wolfe SM. Statement before the FDA Endocrine and Metabolic Drugs Advisory Committee meeting on troglitazone, March 26, 1999. Washington, D.C.: Public Citizen, 26 March 1999. HRG Publication #1476.
Citizen's petition to immediately require class labeling for the diabetes drugs troglitazone (Rezulin), rosiglitazone (Avandia) and pioglitazone (Actos). Washington, D.C.: Public Citizen, 7 March 2000. (HRG Publication # 1514).
Patients, doctors not warned of danger of new diabetes drugs. Public Citizen petitions FDA to revise labels for three drugs. Washington, D.C.: Public Citizen, 7 March 2000.
Wolfe SM. Letter to the FDA requesting a criminal investigation of Warner Lambert / Parke Davis for what appears to be illegally delaying the submission of data known to the company before troglitazone was marketed. Washington, D.C.: Public Citizen, 14 March 2000. (HRG Publication#1515).
Wolfe SM. Letter to Donna Shalala, Secretary of the Department of Health and Human Services urging that they implement and enforce the Code of Ethics for Government (HRG Publication #1516).
Back to Resources page
Home | History | Resources | About the author | Contact
